- Home
- MNMD vs NDMO Comparison
MNMD vs NDMO Comparison
Compare MNMD & NDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNMD
- NDMO
- Stock Information
- Founded
- MNMD 2019
- NDMO 2019
- Country
- MNMD United States
- NDMO United States
- Employees
- MNMD N/A
- NDMO N/A
- Industry
- MNMD Pharmaceuticals and Biotechnology
- NDMO Trusts Except Educational Religious and Charitable
- Sector
- MNMD Health Care
- NDMO Finance
- Exchange
- MNMD Nasdaq
- NDMO Nasdaq
- Market Cap
- MNMD 541.7M
- NDMO N/A
- IPO Year
- MNMD N/A
- NDMO N/A
- Fundamental
- Price
- MNMD $7.08
- NDMO $10.21
- Analyst Decision
- MNMD Strong Buy
- NDMO
- Analyst Count
- MNMD 8
- NDMO 0
- Target Price
- MNMD $26.29
- NDMO N/A
- AVG Volume (30 Days)
- MNMD 1.2M
- NDMO 218.6K
- Earning Date
- MNMD 08-12-2025
- NDMO 01-01-0001
- Dividend Yield
- MNMD N/A
- NDMO 6.75%
- EPS Growth
- MNMD N/A
- NDMO N/A
- EPS
- MNMD N/A
- NDMO N/A
- Revenue
- MNMD N/A
- NDMO N/A
- Revenue This Year
- MNMD N/A
- NDMO N/A
- Revenue Next Year
- MNMD N/A
- NDMO N/A
- P/E Ratio
- MNMD N/A
- NDMO N/A
- Revenue Growth
- MNMD N/A
- NDMO N/A
- 52 Week Low
- MNMD $4.70
- NDMO $8.99
- 52 Week High
- MNMD $10.44
- NDMO $11.24
- Technical
- Relative Strength Index (RSI)
- MNMD 51.96
- NDMO 60.93
- Support Level
- MNMD $6.40
- NDMO $9.95
- Resistance Level
- MNMD $7.29
- NDMO $10.04
- Average True Range (ATR)
- MNMD 0.44
- NDMO 0.10
- MACD
- MNMD -0.06
- NDMO 0.01
- Stochastic Oscillator
- MNMD 64.08
- NDMO 65.00
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).